Hepatitis B virus infection can generally be divided into transient infection and chronic persistent infection. If older children (over 7 years old) or adults are infected with hepatitis B virus, whether it is asymptomatic recessive infection that can produce specific immune response or symptomatic dominant infection (manifested as acute hepatitis), most infected people are transient infection, and their hepatitis B virus will eventually be completely eliminated, and only a few infected people will become chronic hepatitis B patients or chronic hepatitis B virus carriers. Because acute infection is mostly self-limited, its treatment is not complicated. The treatment of acute hepatitis includes reasonable rest, proper nutrition and necessary drugs, mainly rest and nutrition, and the types of drugs should not be too many to avoid increasing the burden on the liver. Generally, antiviral drugs such as interferon are not used. As for the recessive infection, most of them are difficult to find, and the virus has been removed unconsciously and gained specific immunity. Whether it is recessive infection or dominant infection, the specific immunity produced by the body in the process of clearing the virus has a protective effect on the body and can resist the re-invasion of hepatitis B virus.

The study found that the younger the infection age, the greater the probability of persistent infection and becoming a chronic hepatitis B virus carrier or chronic hepatitis B patient. If the infection is caused by vertical mother-to-child transmission during the perinatal period (from 28th week of pregnancy to postpartum 1 week), and no blocking measures are taken, most babies will become chronic virus carriers or chronic hepatitis B patients in the future. Whether it is a chronic hepatitis B virus carrier or a chronic hepatitis B patient, it is unlikely that the virus in the body will naturally turn negative. Even with the influence of drugs, immune pressure and other factors, the probability of E antigen turning negative is very small, the possibility of surface antigen turning negative is even smaller, and the core antibody will hardly turn negative. But generally speaking, the treatment of chronic persistent infection, mainly chronic hepatitis B, is an unsolved problem. As for chronic hepatitis B virus carriers, no matter what method is adopted, the clearance rate is lower. At present, there is no negative conversion of hepatitis B virus in the treatment standards of hepatitis B at home and abroad. Therefore, it is not easy to completely eliminate the chronic persistent infection of hepatitis B virus. If the virus is not completely eliminated, the so-called "radical cure" will be impossible.